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Letters to the Editor
Coenzyme Q10
in Statin-Associated Myopathy
The excellent review by Macroff and Thompson titled “The role of
coenzyme Q10 on statin-associated myopathy” (1) concludes that
insufficient evidence exists for supplementation to treat or prevent
myopathy.
However, the authors recommend its use “if only via placebo
effect.” Should we not first be certain that statin-induced inhibition
of the farnesyl (and dolichol) pathways does not contribute to the
many pleiotropic benefits of statins before we attempt to “correct”
them?
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Reply
Dr. Wolinsky raises an interesting issue. Statins block the rate-
limiting enzyme in the mevalonate pathway reducing cholesterol
production, but also reduce production of farnesyl and geranyl-
geranyl pyrophosphate. These molecules participate in post-
translational modification or prenylation of the Ras superfamily
guanosine triphosphatases or small G proteins. Small G proteins
are involved in cell signaling and proliferation. Statin inhibition of
these G proteins decreases vascular smooth muscle hypertrophy
and proliferation, improves endothelial function, and reduces
angiotensin I receptor expression (1). It may also explain the statin
antiarrhythmic effect in atrial fibrillation (2).
Coenzyme Q10 (Q10) supplementation should not affect small
G protein production since Q10 is not involved in the G protein
prenylation process. Furthermore, we recommended that Q10
supplementation be “tested” or “trialed” (3) only in statin myalgic
patients to allow ongoing statin treatment.
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Can Critically Short
Telomeres Cause Functional
Exhaustion of Progenitor Cells
in Postinfarction Heart Failure?
With great interest we read the article of Kissel et al. (1) on the
selective functional exhaustion of progenitor cells in patients with
ischemic cardiomyopathy (ICM) compared with nonischemic
dilated cardiomyopathy. As stated by the authors, obviously this
clinical study cannot disclose the potential mechanisms underlying
the functional impairment of progenitor cells. However, circum-
stantial evidence for a very reasonable explanation for the selective
exhaustion of (progenitor) cells in ICM could have been easily
obtained. Cells with telomeres reaching a critical length become
genomically unstable, become apoptotic, or enter replicative senes-
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